BWA
VRTX icon

Basecamp Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Basecamp Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Buy
826
+38
+5% +$16.8K 0.08% 148
2026
Q1 		$352K Sell
788
-1
-0.1% -$466 0.07% 172
2025
Q4 		$358K Buy
+789
New +$340K 0.08% 157

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Basecamp Wealth Advisors's VRTX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 4.8% in Q2 2026, buying an estimated $16.8K and bringing the position to 826 shares worth $410K. The position accounts for 0.08% of the portfolio, ranked #148.

Basecamp Wealth Advisors first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,738 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Basecamp Wealth Advisors held 826 shares of Vertex Pharmaceuticals worth $410K as of Q2 2026.
  • Basecamp Wealth Advisors bought 38 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.8K.
  • Vertex Pharmaceuticals made up 0.08% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #148 holding.
  • Basecamp Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,738 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.